Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Cyclobenzaprine recalled?

Yes — there is an active recall. 1 ongoing FDA recall mention Cyclobenzaprine (8 total). Check the affected lots below.

Most common reason: Labeling / mix-up (3 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Cyclobenzaprine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Cyclobenzaprine recalls on record

none so far in 2026; 8 on record, newest first
Class I · High risk

Cyclobenzaprine Hydrochloride Tablets

Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).

Ongoing Labeling / mix-up Unichem Pharmaceuticals USA Inc. NDC 29300-415-19 D-0655-2025
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 57237-266-01 D-0776-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 70199-014-01 D-0775-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 0591-3330-01 D-0774-2021
Class II · Moderate risk

Cyclobenzaprine HCl Tablets

Labeling; Label Mix up; cartons labeled as Amantadine HCl 100 mg Capsules contain unit dose blister cards of Cyclobenzaprine HCl Tablet, USP 5 mg

Terminated Labeling / mix-up Apace KY LLC D-1036-2017
Class II · Moderate risk

Cyclobenzaprine HCI active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-605-2015
Class II · Moderate risk

Cyclobenzaprine HCL

Labeling: Label Mixup: CYCLOBENZAPRINE HCL, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD46257_62, EXP: 5/15/2014; ATENOLOL, Tablet, 12.5 mg (1/2 of 25 mg), NDC 63304062101, Pedigree: AD73525_1, EXP: 5/30/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-972-2014